Minimal Invasive Treatments for Renal Cell Carcinoma

Sarcomatoid Transrormation of Chromophobe Renal Cell Carcinoma

Advanced treatments in non-clear renal cell carcinoma.

PURPOSE To focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma (RCC); papillary I and II, chromophobe, and collecting duct. The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them....

Targeted treatments in advanced renal cell carcinoma: focus on axitinib

Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and...

Erratum: Advanced treatments in non-clear renal cell carcinoma.

Dyspnea as the First Manifestation of Silent Renal Cell Carcinoma

Renal cell carcinoma (RCC) accounts for only 3% of adult malignancies, and the lung is the most common site of metastasis of this tumor, which may be accompanied by pleural metastasis. However, solitary pleural involvement is very rare and its presentation with dyspnea as the first manifestation of RCC is extremely rare.We describe a 39-year-old male with episodes of dyspnea dating back 6...